Related Experiment Video
Updated: Jun 2, 2026
Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease
Eric N Taylor1, Eric B Rimm, Meir J Stampfer
1Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. entaylor@partners.org
Insights
Fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and phosphorus are not linked to coronary heart disease (CHD) risk in men with normal kidney function. This study found no significant association between these biomarkers and the development of CHD.
Area of Science:
- Cardiovascular Disease Research
- Biomarker Discovery
- Endocrinology
Background:
- Coronary heart disease (CHD) risk assessment in individuals with normal renal function is crucial.
- Plasma biomarkers including fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and phosphorus have been investigated for their potential role in CHD development.
- Understanding these associations can aid in refining risk prediction models.
Purpose of the Study:
- To prospectively examine the association between plasma FGF23, PTH, and phosphorus levels and the risk of incident coronary heart disease (CHD) in men without chronic kidney disease.
- To determine if these biomarkers can serve as predictors for CHD development in a population with preserved kidney function.
Main Methods:
- A nested case-control study was conducted within the Health Professionals Follow-up Study.
- Plasma samples from 422 men who developed incident CHD (nonfatal myocardial infarction or fatal CHD) over 10 years were analyzed.
- Controls were matched to cases on age, blood collection date, and smoking status, with a 2:1 ratio.
Main Results:
- No statistically significant differences in baseline plasma FGF23, PTH, or phosphorus levels were observed between cases and controls.
- After multivariable adjustment, the odds ratios for incident CHD across increasing quartiles of FGF23 and PTH were not significant.
- Plasma phosphorus showed a trend towards an inverse association with CHD risk, but this did not reach statistical significance (OR 0.72, 95% CI 0.51-1.02).
Conclusions:
- Plasma FGF23, PTH, and phosphorus are not associated with the development of incident CHD in men without chronic kidney disease.
- These biomarkers do not appear to be useful predictors of CHD risk in this specific population.
- Further research may be needed to explore other potential roles or associations of these factors in cardiovascular health.
Background:
Fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and phosphorus all have been proposed as plasma biomarkers for the development of coronary heart disease (CHD) in individuals with normal renal function.
Methods:
In a nested case-control study of men in the Health Professionals Follow-up Study, free of diagnosed cardiovascular disease at blood draw, we prospectively examined associations between plasma FGF23, PTH, and phosphorus and risk of CHD. During 10 years of follow-up, 422 men developed nonfatal myocardial infarction or fatal CHD. Controls were selected in a 2:1 ratio and matched for age, date of blood collection, and smoking status.
Results:
Mean estimated glomerular filtration rate was 86 mL/min per 1.73 m(2) in cases and controls. At baseline, there were no statistically significant differences between cases and controls in plasma levels of FGF23, PTH, or phosphorus. After adjusting for matching factors, family history of myocardial infarction, body mass index, alcohol consumption, physical activity, history of diabetes mellitus and hypertension, ethnicity, region, plasma 25-hydroxyvitamin D, and other factors, the odds ratios for incident CHD for participants in the highest, compared with lowest, quartiles were 1.03 (95% CI 0.70-1.52, P for trend 0.84) for FGF23, 1.20 (95% CI 0.82-1.76, P trend 0.99) for PTH, and 0.72 (95% CI 0.51-1.02, P trend 0.13) for phosphorus.
Conclusions:
Plasma FGF23, PTH, and phosphorus are not associated with the development of incident CHD in men without chronic kidney disease.
Related Concept Videos
01:27Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily regulated...
00:59The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by producing...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:21Skeleton and Calcium Homeostasis
01:40Bone Remodeling
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...